Products
alpha 1 Antichymotrypsin / AACT antibody
Category:
Research Area:
- SPECIFICATIONS
- Product Name
- alpha 1 Antichymotrypsin / AACT antibody
- Catalogue No.
- FNab00318
- Size
- 100μg
- Form
- liquid
- Purification
- Protein A+G purification
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- monoclonal
- Isotype
- IgG2b
- Clone ID
- 8F10
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- serpin peptidase inhibitor, clade A(alpha-1 antiproteinase, antitrypsin), member 3
- Alternative Names
- A1 Antichymotrypsin antibody, AACT antibody, ACT antibody, Alpha 1 antichymotrypsin antibody, GIG24 antibody, GIG25 antibody, Serpin A3 antibody, SERPINA3 antibody
- UniProt ID
- P01011
- Observed MW
- 60 kDa
Application
- Tested Applications
- ELISA, WB, IHC
- Recommended dilution
- WB: 1:1000-1:10000; IHC: 1:20-1:300
Validated Images
human blood tissue were subjected to SDS PAGE followed by western blot with FNab00318(AACT antibody) at dilution of 1:5000
Immunohistochemistry of paraffin-embedded human tonsillitis tissue slide using FNab00318(AACT antibody) at dilution of 1:200
- Background
- Human SerpinA3, also known as Alpha 1-antichymotrypsin(AACT), is a member of the serine protease inhibitor class, and is a plasma alpha globulin glycoprotein which increases in the blood during the inflammatory process. SerpinA3, is also an inhibitor of neutrophil cathepsin G, mast cell chymases and pancreatic chymotrypsin. SerpinA3 is produced primarily in the liver, and is identified as an acute-phase inflammatory protein. SerpinA3 deficiency has been associated with liver disease. SerpinA3 has also been implicated in the pathology of a number of devastating human diseases including chronic obstructive pulmonary disease(COPD), Parkinson’s disease(PD), Alzheimer’s disease(AD), Stroke, Cystic Fibrosis, Cerebral Haemorrhage and Multiple System Atrophy.